Curie Bio

Curie.Bio is a venture capital firm focused on early-stage biotechnology therapeutics companies. It combines a seed-stage (and Series A) investment vehicle with an in-house operating unit staffed by drug hunters, drug makers and scientific experts who work alongside portfolio founders. Sources describe the firm as a "drug discovery copilot" as well as an investor, providing support on target selection, hiring, data evaluation, regulatory strategy and Series A fundraising, and giving founders access to vetted vendors and services.

The firm was co-founded by Alexis Borisy (operating chairman), Zach Weinberg (co-founder and CEO per one source, listed elsewhere as investor) and Christoph Lengauer (co-founder and chief scientific officer). Chris De Savi is listed as chief scientific officer and partner. Sources give a founding year of 2022, with one profile also citing 2023 in its origin narrative. Reported headquarters vary across sources: one profile lists New York City, an SEC-filing-derived directory lists Cambridge, Massachusetts for the Series A fund entity, and another lists only the United States.

Curie.Bio has closed three funds: Curie Bio Seed Fund I (announced February 2023, with $520M reported as raised across the venture, originally targeting $275M), Curie Bio Series A Fund I (closed June 2024 at $380M; a Form D-derived listing shows $377M in February 2024), and Curie Bio Seed Fund II ($342.1M, first sale January 17, 2025, from 46 investors). By early 2025 the firm reported nearly $1B raised in total and a portfolio of 20 early-stage therapeutics companies.

Founding story

Alexis Borisy, previously at Third Rock Ventures for nearly a decade, and entrepreneur Zach Weinberg argued that the standard venture model left scientific founders with very small equity stakes—sometimes 1% or less—and required independent founders to cede control at the seed or Series A stage. They launched Curie Bio with the stated aim to "free the founders." Christoph Lengauer is also listed as a co-founder; he and Borisy had previously helped launch biotech companies through Third Rock Ventures, while Weinberg's background includes Alphabet/Google and founding healthcare startups.

Business model

Curie.Bio operates two linked entities: an investment vehicle deploying seed and Series A capital into biotech therapeutics startups, and a services/accelerator unit that supplies in-house drug discovery expertise and vendor access to portfolio companies. It invests directly into existing entities, creates focused spinouts, and helps founders build companies from scratch.

As a venture capital firm, returns derive from equity stakes in portfolio therapeutics companies; the firm also operates a services unit supporting those companies.

Traction

Nearly $1B raised across three funds by early 2025 and a portfolio of about 20 early-stage therapeutics companies at that time; one directory reports a larger tracked investment count and $1.2B AUM. The firm's first portfolio company graduation was Forward Therapeutics in 2023.

Latest developments

Most recent disclosed fundraising is the $342.1M Curie Bio Seed Fund II reported in January 2025. A directory profile references a Founder Guide dated Q1 2026 and lists Greg Carven as managing partner.